Meet the Team
Dr Colin O’Dowd
Head of Medicinal Chemistry
Colin manages the medicinal chemistry, ADMET and CADD groups within Almac Discovery bringing to bear his experience in chemistry contract research from his 9 year tenure in Almac Sciences.Click to Read More
Colin has broad medicinal chemistry skills, he and his team have recently worked on Discovery’s kinase and deubiquitylating enzyme programmes and platform. He was heavily involved in implementing and delivering the initial phases of the highly successful industry-academia research collaboration between Almac Discovery and Queen’s University Belfast which continues with the Centre for Precision Therapeutics in 2016.
He has a Ph.D in synthetic organic chemistry from Queen’s University.
Dr Graham Cotton
Senior R&D Group Leader
Graham joined Almac from the acquisition of Albachem and subsequently joined Almac Discovery to bring expertise in peptide and protein chemistry. Graham has responsibility for the technical management of Discovery’s Protein Drug Conjugate key research focus within Almac Discovery and was important in the discovery of the peptide clinical candidate, ALM201.Click to Read More
Before moving to Albachem Graham worked at Amersham Biosciences prior to this he held post-doctoral positions at University of Edinburgh and Rockefeller University, New York. He has a Ph.D from University of Edinburgh.
Dr Gerald Gavory
Head of Biology
Gerald has responsibility for the company’s drug discovery and pre-clinical development activities and was instrumental in implementing the deubiquitylating enzyme research platform at Almac Discovery. Prior to joining Almac Discovery in 2010, Gerald worked at Merck & Co as a senior scientist where he notably contributed towards the identification and development of PARP inhibitors including Niraparib (MK-4827).Click to Read More
Gerald was a post-doctoral fellow at Cambridge University and received his PhD in Biological Sciences in 2003 from the same university in the laboratory of Prof. S. Balasubramanian.
Dr Martin Wiles
Vice President Business Development & Licensing
Martin joined Almac Discovery in November 2014 and has responsibility for all commercial activities. He has over 20 years of experience from across medtech, healthcare services and pharmaceutical development sectors, the latter in both small molecule and biopharmaceuticals.Click to Read More
Prior to Almac Discovery Martin was Senior Vice President of Business Development at BioInvent International AB where he was responsible for several transformative collaborations, including an oncology deal with Roche for which he won the Scrip Awards Licensing deal of the year. Before taking on the role at Bioinvent he held numerous senior commercial, strategic, technical and operational roles within the listed biotechs, K S BioMedixs PLC and BioCompatibles PLC.
He has a Ph.D and MBA.
Dr Stephen Barr
President & Managing Director, Almac Discovery
Stephen is a member of the Almac Group Executive Management and President and Managing Director of both Almac Discovery and Almac Sciences. He was instrumental in establishing Almac Discovery and has had overall responsibility for strategic, financial and operational leadership ever since.Click to Read More
In 2004 Stephen saw the opportunity to acquire Albachem for Almac Sciences Division which subsequently enabled key personnel to join Almac Discovery to strengthen our peptide and protein chemistry capabilities and support our first clinical candidate ALM201. Later Stephen set up the unique relationship with the Cancer Centre for Research and Cellular Biology (CCRCB) at Queen’s University which seeks to consolidate Discovery’s oncology focus.
Stephen has a Ph.D in synthetic chemistry.
Dr Tim Harrison
Vice President Discovery Chemistry
Tim joined Almac Sciences in 2006 as Vice President of Research and Development before moving to Almac Discovery on its establishment in 2008: an initiative he had played a key role in planning and championing. He now has responsibility for all R&D activities and for coordinating the relationship with Queen’s University which, most recently, is via the Centre for Precision Therapeutics.Click to Read More
Prior to Almac Tim spent 15 years at Merck, Sharp and Dohme where he had involvement with their γ-secretase programme and the now marketed Substance P antagonist Emend® for chemotherapy-induced nausea. For his work with Emend® he received the Thomas Alva Edison Patent Award.